Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 600 mg/6 mL)
Drug ClassMonoclonal antibodies directed against the protective antigen of Bacillus anthracis
Ongoing and Completed


  • Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Product Monograph / Prescribing Information

Document TitleYearSource
Anthim (obiltoxaximab) Prescribing Information.2019Therapeutics, Inc., Parsippany, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Assessment report: obiltoxaximab SFL.2020EMA

Clinical Practice Guidelines